![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SAFETY AND EFFICACY OF PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED WITH PEGINTERFERON ALFA-2a (ALFA-2a) IN HCV-INFECTED PATIENTS (G1/2/3) WITH COMPENSATED CIRRHOSIS: EMERGE PHASE 2b EFFICACY AND SAFETY RESULTS THROUGH WEEK 12
|
|
|
Reported by Jules Levin
22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei International Convention Center, February 16-19, 2012
RODRIGUEZ-TORRES M,1 HILLSON J,2 LAWITZ E,3 VARGAS H,4 VIERLING J,5 HORGA A,6 GRAY T,2 XU D,2 LOPEZ-TALAVERA JC,6
1FUNDACION DE INVESTIGACION, SAN JUAN, PUERTO RICO; 2ZYMOGENETICS/BMS, SEATTLE, WA, USA; 3ALAMO MEDICAL RESEARCH, SAN ANTONIO, TX, USA; 4 MAYO CLINIC, PHOENIX, AZ, USA; 5BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX, USA; 6BRISTOL-MYERS SQUIBB, WALLINGFORD, CT, USA
![APASL1.gif](../images/022712/022712-1/APASL1.gif)
![APASL2.gif](../images/022712/022712-1/APASL2.gif)
![APASL3.gif](../images/022712/022712-1/APASL3.gif)
![APASL4.gif](../images/022712/022712-1/APASL4.gif)
![APASL5.gif](../images/022712/022712-1/APASL5.gif)
![APASL6.gif](../images/022712/022712-1/APASL6.gif)
![APASL7.gif](../images/022712/022712-1/APASL7.gif)
![APASL8.gif](../images/022712/022712-1/APASL8.gif)
![APASL9.gif](../images/022712/022712-1/APASL9.gif)
![APASL10.gif](../images/022712/022712-1/APASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|